These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 9693271)

  • 1. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.
    Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J
    Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.
    Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J
    Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study.
    Stein DS; Lyles RH; Graham NM; Tassoni CJ; Margolick JB; Phair JP; Rinaldo C; Detels R; Saah A; Bilello J
    J Infect Dis; 1997 Nov; 176(5):1161-7. PubMed ID: 9359714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
    Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
    Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.
    Fahey JL; Taylor JM; Manna B; Nishanian P; Aziz N; Giorgi JV; Detels R
    AIDS; 1998 Sep; 12(13):1581-90. PubMed ID: 9764776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
    Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
    N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.
    Savès M; Morlat P; Chêne G; Peuchant E; Pellegrin I; Bonnet F; Bernard N; Lacoste D; Salamon R; Beylot J
    Clin Immunol; 2001 Jun; 99(3):347-52. PubMed ID: 11358430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
    Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
    AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.
    Aziz N; Nishanian P; Taylor JM; Mitsuyasu RT; Jacobson JM; Dezube BJ; Lederman MM; Detels R; Fahey JL
    J Infect Dis; 1999 Apr; 179(4):843-8. PubMed ID: 10068579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune activation markers and AIDS prognosis.
    Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
    AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses.
    Lederman MM; Kalish LA; Asmuth D; Fiebig E; Mileno M; Busch MP
    AIDS; 2000 May; 14(8):951-8. PubMed ID: 10853976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.
    Rizzardi GP; Barcellini W; Tambussi G; Lillo F; Malnati M; Perrin L; Lazzarin A
    AIDS; 1996 Nov; 10(13):F45-50. PubMed ID: 8931778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
    Halota W; Jaruga B; Pawłowska M
    Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
    Mellors JW; Muñoz A; Giorgi JV; Margolick JB; Tassoni CJ; Gupta P; Kingsley LA; Todd JA; Saah AJ; Detels R; Phair JP; Rinaldo CR
    Ann Intern Med; 1997 Jun; 126(12):946-54. PubMed ID: 9182471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.
    Ashton LJ; Carr A; Cunningham PH; Roggensack M; McLean K; Law M; Robertson M; Cooper DA; Kaldor JM
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):117-21. PubMed ID: 9462921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.